吉非替尼联合卡培他滨三线治疗晚期结肠癌1例
被引量:3
Gefitinib Combined with Capecitabine as A Third-line Treatment for Advanced Colon Cancer: Report of A Case
摘要
病例:患者女,51岁,2007年6月22日于外院行体检时查腹部CT示“肝占位”,结肠镜病理示“结肠腺癌”。
出处
《胃肠病学》
2012年第10期639-640,共2页
Chinese Journal of Gastroenterology
关键词
结肠肿瘤
吉非替尼
卡培他滨
肿瘤转移
治疗
Colonic Neoplasms
Gefilinib
Capecitabine
Neoplasm Metastasis
Therapy
参考文献9
-
1Tol J, Koopman M, Cats A, et a1. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer [JJ. N Engl J Med, 2009, 360 (6) : 563-572.
-
2Bitossi R, Sculli CM, Tampellini M, et aI. Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients [ J ] . Anticancer Res, 2008, 28 (5B) : 3055-3060.
-
3Gholam D, Giacchetti S, Brezault-Bonnet C, et al. Chro?nomodulated irinotecan, oxaliplatin, and leucovorin?modulated 5-fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer [ J J . Oncologist, 2006 , 11 (10): 1072-1080.
-
4Ardavanis AS, Ioannidis GN, Orphanos GS, et aI. Salvage treatment with single-agent capecitabine in patients with heavily pretreated advanced colorectal cancer [J]. Anticancer Res, 2006, 26 (2B) : 1669-1672.
-
5Van Cutsem E, Kohne CH, Hitre E, et a1. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer [J]. N Engl J Med, 2009, 360 (14) : 1408-1417.
-
6Huang S, Armstrong EA, Benavente S, et aI. Dual-agent molecular targeting of the epidermal growth factor receptor ( EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor [ J ] . Cancer Res, 2004, 64 (15): 5355-5362.
-
7Chau I, Cunningham D, Hickish T, et a1. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I - IT study [J]. Ann Oncol, 2007, 18 (4) : 730-737.
-
8Kuo T, Cho CD, Halsey J, et a1. Phase IT study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancerj L], J Clio Oncol , 2005, 23 (24): 5613-5619.
-
9Waddell T, Gollins S, Soe W, et aI. Phase IT study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study [J]. Cancer Chemother Pharmacol , 2011, 67 (5): 1111-1117.
同被引文献24
-
1朱辉.希罗达治疗结肠癌的毒副反应分析与护理[J].医学信息(医学与计算机应用),2016,29(26):164-165. 被引量:1
-
2Ribeiro SM,Braga CB,Peria FM,et al.Effect of Zinc Supplementation on Antioxidant Defenses and Oxidative Stress Markers in Patients Undergoing Chemotherapy for Colorectal Cancer:a Placebo-Controlled,Prospective Randomized Trial[J].Biol Trace Elem Res,2015,1(12):118-120.
-
3Al-Shamsi HO,Kee BK,Tetzlaff MT,et al.Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer[J].J Gastrointest Oncol,2015,6(3):40-43.
-
4Simunovic MR,DeNardi FG,Coates AJ,et al.Product analysis and initial reliability testing of the total mesorectal excision-quality assessment instrument[J].Ann Surg Oncol,2014,21(7):2274-2279.
-
5Vedat Bayoglu I,Yildiz I,Varol U,et al.Comparison of first-line bevacizumab in combination with mFOLFOX6or XELOX in metastatic colorectal cancer[J].J BUON,2015,20(2):460-467.
-
6Bongiovanni D,Bassetti B,Kupatt C,et al.Role of bone marrow-derived CD133+stem cells in cardiac regeneration:from experimental to clinical trials[J].G Ital Cardiol(Rome),2014,15(6):355-362.
-
7Hansen M,Nyby S,Eifer M?倠ller J,et al.Intracoronary Injection of CD34-Cells in Chronic Ischemic Heart Failure:7Years Follow-Up of the DanCell Study[J].Cardiology,2014,129(2):69-74.
-
8孙娜,田菲.扶正合剂联合希罗达治疗结肠癌30例[J].江西中医药,2010,41(1):37-38. 被引量:3
-
9庄志祥,沈旭东,沈丽琴,张玉松,陆玉峰,初学.雷替曲塞与5-氟尿嘧啶联合奥沙利铂治疗晚期结直肠癌的疗效比较[J].苏州大学学报(医学版),2010,30(3):573-576. 被引量:46
-
10黄江远.晚期结肠癌患者姑息性支架置入的临床意义和疗效[J].临床和实验医学杂志,2011,10(16):1278-1279. 被引量:1
二级引证文献3
-
1谢华辉,乔建国,罗靖,李明堃,黄安华.黄芪多糖与白介素-2联合FOLFOX4化疗方案用于晚期结直肠癌治疗的临床研究[J].肿瘤药学,2016,6(6):418-422. 被引量:4
-
2李书有,黄广优,张珍妮,苏凤婵,陆伟.阿帕替尼联合FOLFOXIRI方案治疗不可切除结直肠癌肝转移患者的疗效与安全性观察[J].结直肠肛门外科,2019,25(2):164-167. 被引量:6
-
3施志杰.阿帕替尼治疗晚期结直肠癌的有效性和安全性[J].临床医学,2021,41(5):90-93. 被引量:1
-
1张玲,王彩云,韩风,韩有志.误诊成肝占位的原发性腹膜后肿瘤的临床分析(附5例分析)[J].中原医刊,1996,23(12). 被引量:1
-
2林宝钗,邵岚,张贝贝,何春晓,郑蕾,洪卫,娄广媛,张沂平.厄洛替尼在晚期非小细胞肺癌二线和三线治疗疗效比较[J].中国现代医生,2012,50(29):52-54. 被引量:1
-
3鲍明亮,毕清,田青,赵明利,任宏轩.埃克替尼二、三线治疗48例晚期非小细胞肺癌[J].中国肿瘤,2014,23(3):249-252. 被引量:5
-
4周晓娟,王瑾.培美曲塞联合奥沙利铂三线治疗非小细胞肺癌1例[J].肿瘤预防与治疗,2011,24(1):53-54.
-
5张殿宝,张宪芬,郭艳珍,张治业,姚俊.吉西他滨联合多西他赛三线治疗复发小细胞肺癌的临床观察[J].中国医药科学,2015,5(19):97-99. 被引量:3
-
6李元青,孙红.替吉奥单药三线治疗老年晚期胰腺癌1例报道[J].实用肿瘤杂志,2014,29(1):90-92. 被引量:5
-
7熊峰,陶敏,段卫明,王振兴.西妥昔单抗联合伊立替康三线治疗晚期结直肠癌的疗效观察[J].中华肿瘤防治杂志,2008,15(22):1759-1760. 被引量:7
-
8李廷,徐益元,於伟民.吉非替尼治疗晚期非小细胞肺癌15例临床观察[J].中国乡村医药,2011,18(3):10-11. 被引量:1
-
9毕元溪.33例肝占位彩色多普勒超声诊断与手术病理对照[J].吉林医学信息,1994(12):3-3.
-
10黄诚,林根.分子靶向药物在晚期非小细胞肺癌二三线治疗中的应用[J].肿瘤学杂志,2012,18(12):888-894. 被引量:1